Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity

Trygve Holmøy1,2, Kristin Ingelev Loken-Amrsrud3, Seren Jacob Bakke4, Antonie G. Beiske5, Kristian S. Bjerve6, Harald Hovdal7, Finn Lilleås8, Rune Midgard9,10, Tom Pedersen11, Jutrate Šaltytė Benth12,13, Øivind Torkildsen13,14, Stig Wergeland13,14, Kjell-Morten Myhr13,14, Annika E. Michelsen15, Pål Aukrust15,2, Thor Ueland15,2

1 Department of Neurology, Akershus University Hospital, Lørenskog, Norway, 2 Institute of Clinical Medicine, University of Oslo, Oslo, Norway, 3 Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway, 4 Department of Neuroradiology, Oslo University Hospital, Oslo, Norway, 5 Multiple Sclerosis Centre Hakadal, Hakadal, Norway, 6 Department of Medical Biochemistry, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 7 Department of Neurology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 8 Curato Oslo, Oslo, Norway, 9 Department of Neurology, Molde Hospital, Molde, Norway, 10 Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway, 11 Unilabs Drammen, Drammen, Norway, 12 Helse Sør-Øst Health Services Research Centre, Akershus University Hospital, Lørenskog, Norway, 13 Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway, 14 KG KG Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Bergen, Norway, 15 Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

Abstract

Background: Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the relationship between serum levels of inflammation markers and MRI activity in patients with relapsing remitting MS, as well as the effect of ω-3 fatty acids on these markers.

Methods: We performed a prospective cohort study in 85 relapsing remitting MS patients who participated in a randomized clinical trial of ω-3 fatty acids versus placebo (the OFAMS study). During a period of 24 months 12 repeated magnetic resonance imaging (MRI) scans and nine serum samples were obtained. We measured 10 inflammation markers, including general down-stream markers of inflammation, specific markers of up-stream inflammatory pathways, endothelial action, and matrix regulation.

Results: After Bonferroni correction, increasing serum levels of CXCL16 and osteoprotegerin were associated with low odds ratio for simultaneous MRI activity, whereas a positive association was observed for matrix metalloproteinase (MMP) 9. CXCL16 were also associated with low MRI activity the next month, but this was not significant after Bonferroni correction. In agreement with previously reported MRI and clinical results, ω-3 fatty acid treatment did not induce any change in the inflammation markers.

Conclusions: Serum levels of CXCL16, MMP-9, and osteoprotegerin reflect disease activity in MS, but are not affected by ω-3 fatty acid treatment. CXCL16 could be a novel biomarker and potential predictor of disease activity in MS.

Citation: Holmøy T, Loken-Amrsrud KL, Bakke SJ, Beiske AG, Bjerve KS, et al. (2013) Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity. PLoS ONE 8(9): e75021. doi:10.1371/journal.pone.0075021

Editor: Pablo Villoslada, Institute Biomedical Research August Pi Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Spain

Received March 19, 2013; Accepted August 8, 2013; Published September 19, 2013

Copyright: © 2013 Holmøy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was partly supported by Merck-Serono, Pronova Biocare, Bayer Schering, Innlandet Hospital Trust, The Western Norway Regional Health Authority, Odd Fellow Research Foundation for multiple sclerosis, Kåre Wierners’s Legacy and The Norwegian MS Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: FL is employed by Curato Oslo and Tom Pedersen by Unilabs. The study was partly supported by Merck-Serono, Pronova Biocare and Bayer Schering. KILA has received travel support and an unrestricted research grant from Biogen Idec and travel support from Merck Serono. KMM has received honoraria for lecturing, participation in pharmaceutical company sponsored clinical trials, and travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono and Sanofi Aventis. HH has participated in pharmaceutical company sponsored clinical trials and received travel support from Merck Serono, Biogen Idec and Bayer Schering. KILA has received travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono and Sanofi Aventis. TH has received speaker honoraria and travel support from Sanofi Aventis, Biogen Idec, Bayer Schering, Novartis and Merck Serono. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: trygve.holmoy@medisin.uio.no
Introduction

The inflammatory response in multiple sclerosis (MS) involves a complex interaction between T cells, B cells, macrophages, dendritic cells, and endothelial cells. Whereas several inflammatory cytokines and growth factors have been suggested as potential mediators [1], their regulation and relative importance are not clear. Moreover, the immunopathogenesis of MS also involves matrix remodeling, including activation of various matrix degrading enzymes such as matrix metalloproteinases (MMPs) [2]. In addition, inflammatory mediators could also mediate neuroprotection and repair [3,4].

Current MS treatments have limited effect and complementary treatments, including ω-3 fatty acids (FA), are used by many patients [5]. However, although ω-3 FA are suggested to have anti-inflammatory properties [6–8], the evidence underpinning their ability to modulate inflammation in MS is largely unknown. We have recently reported that the ω-3 FA in Multiple Sclerosis (OFAMS) study, a randomized clinical trial of 1350 mg eicosapentaenoic acid (EPA) and 850 mg docosahexaenoic acid (DHA) daily versus placebo (corn oil), failed to show any effect on disease activity as assessed by magnetic resonance imaging (MRI) [9]. Whether this reflects an inability to modulate inflammation was not examined in the primary report.

The aim of this sub-study was to assess (i) the association between inflammatory markers and simultaneous or subsequent MRI activity in the OFAMS study population, and (ii) whether treatment with ω-3 fatty acids affects serum markers of inflammation. We examined general down-stream markers of inflammation including pentraxin 3 (PTX3), osteopontin (OPN), soluble tumor necrosis factor receptor type 1 (sTNF-R1), osteoprotegerin (OPG) and interleukin (IL)-1 receptor antagonist (IL-1Ra), more specific markers of upstream inflammatory pathways such as CXCL16, CCL21 and transforming growth factor (TGF) β, markers of endothelial action including activated leukocyte cell adhesion molecule (ALCAM) and MMP-9. All together, these markers will reflect inflammatory pathways (e.g., PTX3, OPG, sTNF-R1, IL-1Ra and CXCL16), the interaction between leukocytes and endothelial cells (e.g., PTX3, ALCAM, CXCL16 and CCL21) and extracellular matrix remodeling (e.g., OPN, OPG, TGFβ and MMP-9), all processes with relevance for the pathogenesis of MS.

Materials and Methods

Ethic statement

The study was approved by the Regional Committee for Medical and Health Research Ethics in Western Norway. All participants gave written informed consent.

Study population and design

The OFAMS study was a randomized double-blind, placebo-controlled trial that included 92 Norwegian patients with relapsing remitting (RR) MS according to the McDonald criteria [9]. The inclusion criteria were age 18-55 years, Expanded Disability Status Scale (EDSS) score ≤5, and ≥1 relapse or new T1-weighted gadolinium enhancing (T1Gd+) or T2-weighted (T2) MRI lesion the last year. None of the patients used immunomodulatory drugs at inclusion. At baseline the patients were randomized to receive either Triomar™ capsules (Pronova Biocare, Sandefjord, Norway) containing 1350 mg of EPA and 850 mg of DHA or placebo (corn oil). At month six all patients started subcutaneous interferon β-1a (IFNβ) injections thrice weekly. Serum was collected at baseline and after 1, 3, 6, 7, 9, 12, 18 and 24 months. MRI was performed at baseline and monthly during months 1 to 9, and after 12 and 24 months.

Measurement of inflammation markers

Serum samples were collected by venipuncture and stored at -80°C until analysis. The concentrations of OPG, sTNF-R1, the chemokines CXCL16 and CCL21, TGFβ1, PTX3, MMP-9, IL-1RA, OPN, and ALCAM were measured by enzyme immunoassay (EIA) obtained from R&D systems (Minneapolis, MN, USA). The analyses were performed simultaneously for all samples from each patient. For each marker consecutive samples from each patient were analysed in neighbouring wells on the same plate. The lab technicians were blinded for treatment as well as MRI activity. The intra- and inter-assay coefficient of variation were <10% for all EIAs.

HLA-DRB1 typing

The HLA-DRB1 status was determined by DNA sequencing using SeCore Loc DRB1 SEQ kit (Invitrogen, Carlsbad, Ca, USA) at the Department of Immunology, Oslo University Hospital, Oslo, Norway.

MRI measurements

As previously described [9], MRI was performed according to a standardised protocol comprising T2-weighted and T1-weighted Gd+ scans using a standard head coil with a 1.5 Tesla MRI Unit. Blinded assessments of T1Gd+ lesions, T2 lesions, and combined unique activity (CUA; the sum of T1Gd+ lesions and new or enlarging T2 lesions) were conducted by two experienced neuroradiologists.

Missing values

Due to restricted amount of serum, not all inflammation markers could be measured at all time points. All inflammation markers were, however, measured in at least three serum samples from each patient, except three patients with none or one measurements of IL-1Ra or ALCAM. Fourteen (2.7%) and nine (2.0%) MRI scans were missing during study months 1-6 and 7-24, respectively. The number of patients, MRI scans and measurements of inflammatory markers contributing to each analysis are provided in the results. Body mass index (BMI) was missing for two patients. Missing values were not replaced.

Statistical analyses

Mean values with standard deviations (SD) are used to describe clinical data and the inflammation markers. The MRI outcomes were skewed towards none or one lesion and were...
Results

Of the 92 patients included in the OFAMS study, sufficient serum or MRI scans were missing from seven. Thus, 85 patients, 55 (65%) women and 30 (35%) men, age 38.7 (8.1) years, BMI 25.8 (4.3), disease duration 1.9 (3.1) years, and EDSS score at baseline 1.9 (0.8) were included in this study. Mean levels of the inflammation markers at baseline and during different phases of the study are shown in Table 1. The concentrations and the proportion of positive MRI scans at each time point throughout the study are given in Table S1. The ICC for log-transformed inflammation markers varied between 0.43 (MMP-9) and 0.77 (CXCL16), implying that between 23% and 57% of the total variation was intra-individual. The mean concentration of most of the inflammation markers before IFNβ treatment differed from that recorded during IFNβ treatment (Table 1). Gender, age, BMI, or the presence of HLA-DRB1*15 were not associated with any of the markers.

The association between inflammatory markers and disease activity as assessed by MRI

To assess whether the inflammation markers reflect disease activity, a logistic regression model for hierarchical data was fitted to estimate the OR for simultaneous MRI activity associated with 1 SD increase in each inflammation marker (Table 2). After Bonferroni correction, increasing concentrations of OPG were associated with lower OR for new T1Gd+ and T2 lesions and CUA (i.e., the combination of the two other MR parameters), and increasing levels of CXCL16 were associated with lower OR for new T1Gd+ lesions and CUA. In contrast to the inverse associations with these markers, increasing concentrations of MMP-9 were associated with more new T1Gd+ lesions. The temporal relationship between MRI activity and CXCL16, OPG and MMP-9 is shown in Figure 1. Less pronounced inverse associations were recorded between MRI activity and IL-1Ra and sTNFR1, and positive associations with TGFβ, but these associations were not significant after Bonferroni correction. None of the associations were influenced by adjusting for gender, age, BMI, or the presence of HLA-DRB1*15 (data not shown).

As shown in Table 1 and Figure 1, the MRI outcomes and also most inflammation markers differed between before and during IFNβ treatment. OR for simultaneous MRI activity associated with each inflammation marker before (month 0-6) and during (month 7-24) IFNβ treatment is shown in Table 3. A clear pattern was observed for OPG which was inversely associated with all MRI outcomes during IFNβ treatment, whereas no associations were recorded before IFNβ treatment. PTX3 was positively associated with new T2 lesions and CUA before, but not during IFNβ treatment.

To assess whether markers of systemic inflammation also predict disease activity, we estimated the relationship between 1 SD increase in each marker and MRI activity one month later (Table 4). The association between CXCL16 and subsequent CUA was equal to that recorded for simultaneous CUA, whereas the ORs for new T1Gd+ and T2 lesions were somewhat higher but in the same order of magnitude as for simultaneous disease activity. Except a weak association between OPG and new T1Gd+ lesions the next month, none of the other inflammation markers were associated with MRI activity the following month. None of the associations with subsequent MRI activity reached a significance level of 0.0017, although the association between CXCL16 and CUA was close (p = 0.0021).

The effect of ω-3 FA treatment on inflammatory markers

We have recently reported that the treatment with EPA and DHA had no influence on disease MRI activity in these patients

Therefore, logarithmically transformed values were used in the statistical analyses. There was a considerable intra-individual variation in logarithmically transformed inflammation markers as measured by the intra-class correlation coefficient (ICC). The association between the inflammation markers and simultaneous or subsequent (one study month later) MRI activity was therefore assessed by a logistic regression model for hierarchical data. The SAS GLIMMIX procedure was used to fit a model with random intercepts for patients and fixed effects for inflammation markers. Only paired measurements of inflammation markers and MRI outcomes were included in the regression model. Due to logarithmic transformation of inflammation markers, odds ratios (OR) for MRI activity associated with each 1 SD increase in inflammation markers were estimated. The impact of gender, age, BMI, and HLA-DRB1*15 status on MRI activity and inflammation markers at different study months was assessed (SAS MIXED procedure). The adjustment for heteroscedastic variances was performed for the association between MRI activity and CXCL16, OPG and MMP-9 is shown in Figure 1. Less pronounced inverse associations were recorded between MRI activity and IL-1Ra and sTNFR1, and positive associations with TGFβ, but these associations were not significant after Bonferroni correction. None of the associations were influenced by adjusting for gender, age, BMI, or the presence of HLA-DRB1*15 (data not shown).
Table 1. Concentrations and intra-class correlation coefficients (ICC) of inflammation markers.

| Inflammation marker | Baseline | Whole study period | Omega-3 | Placebo | No IFB | IFB | p-value |
|---------------------|----------|--------------------|---------|---------|--------|-----|---------|
|                     | N^1      | Mean (SD)^2        | n^3     | Mean (SD)^2 | n^3 | Mean (SD)^2 | n^3 | Mean (SD)^2 | n^3 | Mean (SD)^2 | n^3 | Mean (SD)^2 | n^3 | Mean (SD)^2 |
| PTX3 (ng/ml)        | 80       | 1255 (1150)        | 725     | 1164 (723) | 376 | 1186 (811) | 349 | 1141 (614) | 327 | 1143 (652) | 398 | 1182 (596) | <0.001 |
| sTNF-R1 (pg/ml)     | 81       | 920 (254)          | 733     | 980 (272) | 868 | 981 (276) | 349 | 979 (268) | 331 | 919 (256) | 402 | 1030 (274) | <0.001 |
| CXCL16 (pg/ml)      | 81       | 1262 (772)         | 728     | 1328 (634) | 379 | 1199 (379) | 350 | 700 (394) | 331 | 1468 (662) | 398 | 1419 (595) | <0.001 |
| MMP-9 (pg/ml)       | 81       | 836 (1239)         | 734     | 585 (807) | 434 | 481 (404) | 350 | 700 (394) | 331 | 298 (394) | 402 | 468 (349) | <0.001 |
| CCL21 (pg/ml)       | 80       | 291 (139)          | 328     | 296 (161) | 368 | 311 (127) | 350 | 361 (186) | 330 | 298 (142) | 402 | 352 (172) | <0.001 |
| IL-1Ra (pg/ml)      | 77       | 134 (350)          | 183     | 113 (629) | 76.3 | 258 (230) | 324 | 130 (866) | 394 | 227 (393) | <0.001 |
| OPN (ng/ml)         | 73       | 7.6 (3.9)          | 724     | 10.4 (6.0) | 53.2 | 9.3 (8.2) | 322 | 7.9 (5.7) | 402 | 11.4 (4.9) | <0.001 |
| OPG (pg/ml)         | 73       | 1052 (360)         | 723     | 10.4 (413) | 60.7 | 1062 (490) | 344 | 1212 (288) | 322 | 1050 (425) | 401 | 1214 (389) | <0.001 |
| TGFβ1 (ng/ml)       | 71       | 21.4 (8.1)         | 722     | 20.7 (7) | 45.9 | 19.3 (8.1) | 343 | 19.3 (6.4) | 320 | 20.7 (7.5) | 402 | 19.8 (7.3) | 0.062 |
| ALCAM (ng/ml)       | 69       | 160 (81)           | 663     | 171 (74) | 56.8 | 179 (69) | 326 | 179 (78) | 310 | 170 (74) | 373 | 171 (74) | 0.439 |

1 Number of patients with a baseline measurement; 2 ICC (%) is calculated for logarithmically transformed data with baseline measurements included; 3 Number of measurements in the analyses; 4 Calculated ignoring clustering; 5 p-value from the model from mixed model with random intercepts and heteroscedastic residuals where relevant (irrelevant indicated with *) for logarithmically transformed measurements

doi: 10.1371/journal.pone.0075021.t001

Figure 1. MRI activity and mean concentrations (positive SD) of inflammation markers significantly associated with MRI outcomes throughout the study. All available observations at each time point are included (see Table S1 for numbers). All T1Gd+ lesions are shown at month 0 (baseline). Abbreviations: CXCL16: Chemokine (C-X-C motif) ligand 16, OPG: osteoprotegerin, MMP-9: matrix metalloproteinase 9, T1Gd+: gadolinium enhancing T1 MRI lesion, CUA: combined unique activity.

doi: 10.1371/journal.pone.0075021.g001
**Table 2. Odds ratios for simultaneous MRI activity for each 1 SD increase in each inflammation marker.**

| Inflammation marker | Odds ratio (95% CI) | p-value |
|---------------------|---------------------|---------|
| PTX3 | 1.15 (0.90, 1.49) | 0.25 | 0.98 |
| sTNF-R1 | 0.88 (0.53, 0.88) | 0.22 | 0.005 |
| CXCL16 | 0.56 (0.42, 0.74) | <0.0013 | 0.0013 |
| MMP-9 | 1.37 (1.08, 1.73) | 0.02 | 0.0013 |
| CCL21 | 0.83 (0.64, 1.06) | 0.49 | 0.02 |
| IL-1Ra | 0.77 (0.60, 0.99) | 0.70 | 0.03 |
| OPN | 0.89 (0.72, 1.12) | 0.82 | 0.05 |
| OPG | 0.56 (0.43, 0.72) | 0.55 | 0.13 |
| TGFβ | 1.27 (0.99, 1.62) | 1.39 | 0.05 |
| ALCAM | 0.98 (0.77, 1.25) | 1.03 | 0.05 |

N: Number of measurements included in the analysis of new T2 lesions and combined unique activity; (n): Number of measurements included in the analysis of new T1Gd+ lesions.

1 Analyzed in 85 patients. 2 Analyzed in 84 patients. 3 Significant after Bonferroni correction.

do: 10.1371/journal.pone.0075021.t002

Table 4. Odds ratio for subsequent MRI activity for 1 SD increase in each inflammation marker (MRI outcomes lagged by one month).

| Inflammation marker | Odds ratio (95% CI) | p-value |
|---------------------|---------------------|---------|
| PTX3 | 1.09 (0.81, 1.47) | 0.06 | 0.73 |
| sTNF-R1 | 0.79 (0.58, 1.09) | 0.81 | 0.78 |
| CXCL16 | 0.65 (0.46, 0.93) | 0.80 | 0.02 |
| MMP-9 | 1.17 (0.87, 1.58) | 1.20 | 0.31 |
| CCL21 | 0.75 (0.51, 1.16) | 0.88 | 0.85 |
| IL-1Ra | 0.85 (0.62, 1.17) | 0.86 | 0.82 |
| OPN | 0.91 (0.68, 1.21) | 0.88 | 0.91 |
| OPG | 0.78 (0.57, 1.06) | 0.85 | 0.51 |
| TGFβ | 1.40 (1.00, 1.96) | 1.17 | 0.11 |
| ALCAM | 0.90 (0.66, 1.23) | 0.87 | 0.05 |

N: Number of measurements included in the analysis of new T2 lesions and combined unique activity; (n): Number of measurements included in the analysis of new T1Gd+ lesions.

1 Analyzed in 85 patients. 2 Analyzed in 84 patients. 3 Analyzed in 82 patients.

do: 10.1371/journal.pone.0075021.t004

**Discussion**

We have tested a broad panel of inflammation markers, of which CXCL16 and OPG were inversely, and MMP-9 positively associated with simultaneous MRI activity. Treatment with EPA and DHA did not alter the serum levels of any of these inflammation markers.

Several chemokines and chemokine receptors, including CXCL8, CXCL13, CXCL12, CCL2, and CCL19 have been suggested as possible biomarkers in MS [10–13]. In this study CXCL6 stood out compared to the other markers as it reflected simultaneous MRI activity and was also associated with a trend for low subsequent MRI activity. CXCL6 is expressed on the surface of antigen presenting cells where it serves as a ligand for CXCR6 on T cells and natural killer T cells. The expression of CXCL16 is induced by inflammatory mediators including IFNγ and TNFα, and it can be shed into the circulation as a soluble chemokine that activates CXCR6 expressing cells [14]. Both CXCL16 and CXCR6 are expressed in the CNS, and protect against excitotoxic damage caused by excessive glutamate exposure and oxygen and glucose deprivation [15]. CXCL16 has also been shown to regulate T cell homing to the CNS in experimental autoimmune encephalomyelitis (EAE) [16], and it was recently shown in this model that immature myeloid cells expressing CXCL16 redirect CXCR3 + CXCR6+ and myelin-specific T cells from CNS to lymph nodes [17]. To our knowledge, only one cross-sectional study has previously analyzed CXCL16 levels in MS patients.
levels in patients with MS and other inflammatory CNS diseases compared to controls with non-inflammatory neurological diseases [18]. Very recently CXCL16 was shown to be expressed by macrophages and astrocytes in MS lesions [19]. Our findings call for further studies in larger MS populations with longer follow-up.

Table 3. Odds ratios for simultaneous MRI activity for each 1 SD increase in each inflammation marker before and during interferon beta treatment.

| Inflammation marker | Before interferon beta | During interferon beta |
|---------------------|------------------------|------------------------|
|                     | p-value                | Combined unique activity | New NT2 lesions | New T1Gd+ lesions | p-value | Combined unique activity | New NT2 lesions | New T1Gd+ lesions |
| PTX3                | 0.03                   | 1.48 (1.04, 2.13)       | 1.49 (1.08, 2.07) | 1.16 (0.84, 1.59) | 0.50     | 1.03 (0.71, 1.49)       | 1.06 (0.71, 1.59) |
| sTNF-R1             | 0.64                   | 0.92 (0.64, 1.32)       | 1.01 (0.73, 1.40) | 1.02 (0.71, 1.45) | 0.08     | 0.75 (0.54, 1.04)       | 0.72 (0.50, 1.04) |
| CXCL16              | 0.49                   | 0.88 (0.60, 1.28)       | 0.92 (0.67, 1.28) | 0.75 (0.51, 1.10) | 0.02     | 0.64 (0.45, 0.93)       | 0.63 (0.42, 0.93) |
| MMP-9               | 0.31                   | 1.21 (0.84, 1.76)       | 1.23 (0.88, 1.73) | 1.31 (0.91, 1.89) | 0.90     | 0.81 (0.61, 1.07)       | 0.87 |
| CCL21               | 0.98                   | 0.99 (0.68, 1.45)       | 1.13 (0.80, 1.59) | 0.92 (0.66, 1.30) | 0.90     | 0.92 (0.77, 1.11)       | 0.72 |
| IL-1Ra              | 0.81                   | 0.96 (0.67, 1.39)       | 0.99 (0.71, 1.38) | 1.02 (0.70, 1.47) | 0.98     | 0.95 (0.67, 1.35)       | 0.93 (0.64, 1.35) |
| OPN                 | 0.61                   | 1.12 (0.79, 1.58)       | 1.10 (0.80, 1.51) | 1.10 (0.78, 1.54) | 0.99     | 0.98 (0.73, 1.32)       | 0.79 |
| OPG                 | 0.51                   | 0.93 (0.66, 1.32)       | 1.03 (0.75, 1.40) | 1.00 (0.72, 1.40) | 0.99     | 0.99 (0.73, 1.32)       | 0.79 |
| TGFβ1               | 0.69                   | 1.31 (0.92, 1.88)       | 1.18 (0.86, 1.63) | 1.39 (0.96, 2.03) | 0.99     | 0.96 (0.70, 1.34)       | 0.79 |
| ALCAM               | 0.14                   | 1.04 (0.72, 1.49)       | 1.10 (0.80, 1.53) | 1.20 (0.86, 1.66) | 0.57     | 0.99 (0.64, 1.44)       | 0.89 |

N1 (N2): Number of measurements included in the analysis of new T2 lesions and combined unique activity (new T1Gd+ lesions); N3: Number of measurements included in the analysis; (n): Number of patients included in the analysis.
doi: 10.1371/journal.pone.0075021.t003

reporting higher levels in CSF compared to serum and higher levels in patients with MS and other inflammatory CNS diseases compared to controls with non-inflammatory neurological diseases [18]. Very recently CXCL16 was shown to be expressed by macrophages and astrocytes in MS lesions [19]. Our findings call for further studies in larger MS populations with longer follow-up.

OPG and sTNF-R1 are members of the TNF receptor family, while IL-1Ra is a receptor antagonist. These soluble receptors and receptor antagonists may attenuate the pro-inflammatory activity of their respective ligands, i.e., receptor activator of nuclear factor kappaB ligand (RANKL), TNFα, and IL-1. Injection of sTNF-R1 prevents EAE [20], whereas the role in MS is less clear. IL-1Ra has been linked to MRI activity in MS patients [21], but the study was too small to reach a firm conclusion. Previous small studies have reported higher serum OPG levels in MS patients compared to healthy controls [22], and no difference in CSF OPG levels between patients with MS and patients with non-inflammatory neurological diseases [23]. High serum levels of sTNF-R1 have been reported during [24] and after [25] relapses in longitudinal studies, suggesting a possible protective role in MS patients. A recent cross sectional study was however negative [26]. Our findings that circulating levels of OPG were inversely associated with MRI activity, and the corresponding trends for sTNF-R1 and IL-1Ra, may suggest a beneficial effects of these cytokine modulators in MS, possibly mediated through their ability to block their corresponding pathogenic ligands.

Unlike most of the examined markers, MMP-9 was positively associated with MRI activity. MMP-9 is secreted by activated T cells and microglia, and is involved in the digestion of extracellular matrix and loss of blood brain barrier (BBB).
Further studies are needed to clarify the role of this pluripotent cytokine in MS. It is believed that the main role of TGFβ1 is to maintain immune tolerance and that it protects against inflammatory demyelination [30,31]. However, recent studies suggest that TGFβ1 could induce the generation of autoreactive Th17 cells [32], a subset believed to promote disease activity in MS. In addition, TGFβ1 signaling in the CNS has been shown to precede paralysis in EAE, independent of Th17 cells [33]. Further studies are needed to clarify the role of this pluripotent cytokine in MS.

For several markers, including CXCL16 and MMP-9, analyzing the periods before and during IFNβ treatment yielded weaker associations than those recorded for the whole study period. This is compatible with the well known effect of IFNβ on inflammation and MRI activity in MS, and the marked drop in MRI activity and alteration in the concentrations of inflammation markers between month 6 and 7 recorded in this study. It is therefore likely that IFNβ had a substantial influence on our results. However, as all patients received IFNβ from month 6, we cannot draw definite conclusions on the effect of this treatment. PTX3 was associated with high OR for MRI activity before, but not during IFNβ treatment. Although this observation concurs with a recent report on the association between PTX3 and clinical disease activity [34], it may be an incidental finding.

Our findings corroborate the inability of EPA and DHA to modulate disease activity in MS [9]. Previous studies on the effect of EPA and DHA on inflammatory markers in MS have reached conflicting results. Galli et al. reported a significant decrease in the production of IL-1β, TNFα, IL-2, and IFN-γ in peripheral blood mononuclear cells (PBMC) upon daily supplementation with 3.0 g of EPA and 1.8 g of DHA [35], whereas Weinstock-Guttman et al. found no effect on plasma levels of a range of inflammatory markers of 1.98 g EPA and 1.32 g DHA compared to 6 g olive oil per day [36]. EPA and DHA have also been demonstrated to reduce MMP-9 synthesis in PBMC from MS patients [37]. Diverging results across studies may be due to differences in doses, measurements in PBMC versus serum/plasma, and in the content of the placebo preparations [7]. The corn oil capsules used as placebo in the COFAMS study contained 52% linoleic acid. Although most studies have shown no effect of linoleic acid on systemic inflammation markers [38], we cannot exclude an effect on some of the inflammation markers.

The prospective design with repeated measurements of MRI and inflammation markers in each patient allowed us to capture both intra- and individual variation, and is a strength of this study. The finding that up to 57% of the total variation of log transformed levels of the inflammation markers was inter-individual underscores the advantage of this approach. Moreover, MRI scanning, collection of serum samples and measurement of inflammation markers were standardized in all patients. There are, however, also limitations to this study. The restricted amount of serum did not allow measurement of all inflammation markers in all patients, and the number of patients may have been too low to detect minor effects of ω-3 fatty acids on inflammation markers.
markers that respond rapidly to IFN β, and increased the variability in the latter phase of the study. Any such effect would, however, affect patients on ω-3FA and placebo equally. Moreover, the SD of the inflammation markers was in the same order of magnitude before and during IFN β treatment, arguing against any substantial effect. Another potential weakness is that the interval between MRI scanings was markedly longer at the end of the study. The MRI scans were distributed to capture the high expected disease activity prior to IFN β treatment, and this could potentially influence the ratio between new T1Gd+ lesions and new T2 lesions during different phases of the study. There was, however, an even reduction in new T1Gd+ and T2 lesions after the initiation of IFNβ, and this effect is therefore likely to be minor.

Conclusions

In this longitudinal study serum levels of CXCL16, OPG and MMP-9 reflect MRI activity in RRMS, suggesting that these markers, in particular CXCL16 which also may predict disease activity, could be potential markers of disease activity in MS. Treatment with EPA and DHA did not affect the serum concentrations of these or other inflammation markers. The results obtained in this exploratory study need to be confirmed and should encourage further studies, particularly on CXCL16 as a potential mediator and biomarker in MS.

Supporting Information

Table S1. Concentrations of inflammation markers and frequencies of positive MRI scans throughout the study.

Author Contributions

Conceived and designed the experiments: TH KILA SJB AGB KSB HH FL RM TP KMM PA TU. Performed the experiments: FL TP PA TU AEM. Analyzed the data: TH JSB PA TU. Contributed reagents/materials/analysis tools: FL TP OT SW PA TU AEM. Wrote the manuscript: TH PA TU. Review of the manuscript for intellectual content: KILA OT KMM SJB AGB KSB HH FL RM TP AEM KMM PA TU.

References

1. Graber JJ, Dhib-Jalbut S (2011) Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 305: 1-10. doi:10.1016/j.jns.2011.03.026. Pubmed: 21463872.
2. Romi F, Helgeland G, Gilhus NE (2012) Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur Neurol 67: 121-128. doi:10.1159/000334862. Pubmed: 22262194.
3. Moalem G, Leibowitz-Amril R, Yoles E, Mor F, Cohen IR et al. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5: 49-55. doi:10.1038/4734. Pubmed: 9883836.
4. Kyrissis N, Kozl C, Zocher S, Kroehne V, Kaslin J et al. (2012) Acute inflammation initiates the regenerative response in the adult zebrafish brain. Science 338: 1353-1356. doi:10.1126/science.1228773. Pubmed: 23138980.
5. Schwarz S, Knorr C, Geiger H, Flachenecker P (2008) Complementary and alternative medicine for multiple sclerosis. Mult Scler 14: 1113-1119. doi:10.1177/1352458508092808. Pubmed: 18632773.
6. Zhang W, Li P, Hu X, Zhang F, Chen J et al. (2011) Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. Front Biosci 16: 2653-2670. doi:10.2741/3878. Pubmed: 21622201.
7. Calder PC (2012) Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol 75: 645-662.
8. Mehta LR, Dworin RH, Schwid SR (2009) Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 5: 82-92. doi:10.1038/ncpneur0109. Pubmed: 19193488.
9. Torkildsen O, Wergeland S, Babke S, Beiske AG, Bjerve KS et al. (2006) CXCL16 is elevated in the cerebrospinal fluid versus serum in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci Lett 397: 145-148. doi:10.1016/j.neulet.2005.12.029. Pubmed: 16406320.
10. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R et al. (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115: 192-196. doi:10.1016/S0165-5728(01)00261-2. Pubmed: 11282170.
11. Sellebjerg F, Børnsen L, Khademi M, Krakauer M, Olsson T et al. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73: 2003-2010. doi:10.1212/WNL.0b013e3181c5b457. Pubmed: 19996075.
12. Krumbholz M, Theil D, Steinmeyer F, Cepok S, Hemmer B et al. (2007) CXCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol 190: 72-79. doi:10.1016/j.jneuroim.2007.07.024. Pubmed: 17625430.
13. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P et al. (2006) CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200-211. doi:10.1093/brain/awh680. Pubmed: 16280350.
14. Abel S, Hundhausen A, Mentelein R, Schulte A, Berkthau TA et al. (2004) The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172: 6362-6372. Pubmed: 15128827.
15. Rosito M, Deflorio C, Limatola C, Trettel F (2012) CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS. J Neurosci 32: 3154-3163. doi:10.1523/JNEUROSCI.4046-11.2012. PubMed: 22378888.
16. Fukumoto N, Shimaoka T, Fujimura H, Sakoda S, Tanaka M et al. (2004) Critical roles of CXC chemokine ligand 16 scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 173: 1620-1627. PubMed: 15265890.
17. O’Connor RA, Li X, Blumerman S, Anderton SM, Noelle RJ et al. (2012) Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR5+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system. J Immunol 188: 2093-2101. jimmunol.1101118 doi:10.4049/jimmunol.1101118. Pubmed: 22287779.
18. Le Blanc LM, van Lieshout AW, Adema GJ, van Riel PL, Verbeek MM et al. (2006) CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci Lett 397: 145-148. doi:10.1016/j.neulet.2005.12.029. Pubmed: 16406320.
19. Hendrickx DA, Koning N, Schuurman KG, van Strien ME, van Eden CG et al. (2013) Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. J Neuropathol Exp Neurol 72: 106-118. doi:10.1097/NEN.0b013e3182f79de8. Pubmed: 23354594.
20. Selmaj K, Papierz W, Glabinski A, Kohno T (1995) Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56: 135-141. doi:10.1016/0165-5728(94)00139-F. PubMed: 7860709.

21. Voltz R, Hartmann M, Spuler S, Scheller A, Mai N et al. (1997) Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J Neurol Neurosurg Psychiatry 62: 200-201. doi:10.1136/jnnp.62.2.200-b. PubMed: 9048730.

22. Kurban S, Akpinar Z, Mehmetoglu I (2008) Receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Mult Scler 14: 431-432. doi: 10.1177/1352458507084028. PubMed: 18208894.

23. Hofbauer LC, Cepok S, Hemmer B (2004) Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathol 107: 575-577. doi:10.1007/s00401-004-0854-y. PubMed: 15106011.

24. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P et al. (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 38: 186-193. doi:10.1002/ana.410380210. PubMed: 7544573.

25. Rieckmann P, Martin S, Weichselbraun I, Albrecht M, Kitze B et al. (1994) Serum analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cCAM-1 is an indicator for relapse. Neurology 44: 2367-2372. doi:10.1212/WNL.44.12.2367. PubMed: 7527508.

26. Wang H, Wang K, Wang C, Zhong X, Qiu W et al. (2013) Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 19: 926-931. doi: 10.1177/1352458512457845. PubMed: 23012252.

27. Wang H, Wang K, Wang C, Zhong X, Qiu W et al. (2013) Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 19: 926-931. doi: 10.1177/1352458512457845. PubMed: 23012252.

28. Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A et al. (1995) Cytokine secretion and eicosanoid production in the peripheral mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 56: 143-153. doi:10.1016/0165-5728(94)00140-J. PubMed: 7860710.

29. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P et al. (2005) Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 73: 397-404. doi: 10.1016/j.plefa.2005.05.024. PubMed: 16099630.

30. Shinto L, Marracci G, Baldau-Wagner S, Strethow A, Yadav V, Stuber L et al. (2009) Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids 80: 131-136. doi: 10.1016/j.plefa.2008.12.001. PubMed: 19171471.

31. Johnson GH, Fritsche K (2012) Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J Acad Nutr Diet 112: 1029-1041. PubMed: 22889633.